Study guide Ultimate Study Guide

Clinical Roles and Responsibilities in Hemodialysis

• Registered Nurse (RN) Responsibilities:

  • Oversees and assesses the patient and the patient's treatment throughout the clinical encounter.
  • Develops and implements the comprehensive patient plan of care.
  • Directs clinical interventions.
  • Provides initial patient education.

• Licensed Practical Nurse / Licensed Vocational Nurse (LPN/LVN) Responsibilities:

  • Evaluates and monitors patients during therapy.
  • Completes clinical interventions as delegated by the RN.
  • Reinforces education initially provided by the RN.

• Patient Care Technician (PCT) Responsibilities:

  • Evaluates patients, prepares for, initiates, monitors, and terminates hemodialysis treatments.
  • Reinforces nursing education with patients.

• Physician / Nephrologist Responsibilities:

  • Directs all aspects of patient care.
  • Prescribes and modifies hemodialysis treatment orders, including the dialysate bath formulation, dialyzer size, treatment duration, blood flow rate ($\text{BFR}$), and dialysate flow rate ($\text{DFR}$), based on patient laboratory values, vital signs, physical assessments, and patient complaints.

Renal Anatomy, Physiology, and Pathology

• Anatomy of the Urinary System:

  • Composed of two ($2$) kidneys, two ($2$) ureters, one ($1$) bladder, and one ($1$) urethra.
  • The kidneys produce urine, which is transported by the ureters to the urinary bladder for temporary storage, and subsequently excreted from the body via the urethra.

• Kidney Functions — Mnemonic "A WET BED":

  • A — Acid/Base Balance: Maintenance of blood pH balance.
  • W — Water or Fluid Balance: Regulation of intravascular and extracellular fluid volume.
  • E — Electrolyte Balance: Maintenance of systemic electrolytes ($K^+$, $Na^+$, $Ca^{2+}$, phosphorus).
  • T — Toxin or Waste Product Removal: Elimination of metabolic waste products, including urea and creatinine.
  • B — Blood Pressure Regulation: Hormonal and volume control of systemic blood pressure.
  • E — Erythropoietin Production: Stimulation of red blood cell production within the bone marrow.
  • D — Vitamin D Metabolism: Activation of vitamin D into calcitriol for bone and mineral metabolism.

• Acute Renal Failure (ARF):

  • Onset: Sudden onset.
  • Severity: Severe initial presentation.
  • Reversibility: Usually reversible once underlying causes are addressed.
  • Etiological Examples: Drug toxicity, acute physical trauma, severe dehydration, and systemic or renal infections.

• Chronic Renal Failure (CRF):

  • Onset: Slow, insidious onset.
  • Progression: Progressive and irreversible degradation of nephron function.
  • Permanence: Permanent loss of kidney function requiring renal replacement therapy or transplantation.
  • Etiological Examples: Diabetes mellitus and hypertension are the two most common causes; other causes include glomerulonephritis and congenital renal diseases.

Renal Failure Manifestations and Uremic Syndrome

• Definition of Uremia:

  • A constellation of clinical signs and symptoms directly associated with the toxic buildup of urea and other metabolic waste products in the bloodstream.

• Clinical Signs of Renal Failure:

  • Elevated serum Blood Urea Nitrogen ($\text{BUN}$) and creatinine.
  • Elevated serum phosphorus.
  • Elevated serum potassium ($K^+$).
  • Proteinuria (presence of excessive protein in the urine).
  • Anemia (secondary to decreased erythropoietin production).
  • Nerve damage / peripheral neuropathy.

• Clinical Symptoms of Renal Failure and Uremia:

  • Lethargy and weakness.
  • Persistent headache.
  • Fatigue.
  • Pruritus (itching).
  • Nausea and loss of appetite (anorexia).
  • Yellow-gray appearance of the skin (urochrome pigment deposition).
  • Systemic fluid overload, manifested by shortness of breath and peripheral/pulmonary edema.
  • Restlessness and mental status changes.
  • Hypertension (high blood pressure).

Renal Replacement Therapy Modalities

• Hemodialysis (HD):

  • Mechanism: Uses a surgically created vascular access to withdraw blood from the patient and pump it through an extracorporeal dialyzer.
  • Solute Clearance: Waste products are cleared via diffusion across a semipermeable synthetic membrane.
  • Fluid Clearance: Fluid is removed via ultrafiltration driven by positive and negative pressure gradients.
  • Therapeutic Scope: Does not cure renal failure; functions solely as a replacement for selected excretory and homeostatic functions of the failing kidneys.

• Peritoneal Dialysis (PD):

  • Mechanism: Uses a permanently placed catheter within the peritoneal cavity inside the abdomen.
  • Membrane: The patient's peritoneal membrane, which surrounds abdominal visceral organs, acts as the semipermeable membrane.
  • Clearance Principles: Solutes and metabolic wastes are removed via diffusion; excess fluid is removed via osmosis across the membrane into a dextrose-containing dialysate.
  • Continuous Cycling Peritoneal Dialysis (CCPD): Employs an automated cycler machine to perform timed dialysate infusions and drain exchanges, typically while the patient sleeps.
  • Continuous Ambulatory Peritoneal Dialysis (CAPD): Manual method where dialysate is infused into the peritoneal cavity, dwells for a physician-prescribed duration, and is drained by gravity without a machine.

• Kidney Transplantation:

  • A surgical procedure where a functioning donor kidney from either a living or cadaveric donor is implanted into the recipient.

Biophysical Principles of Hemodialysis

• Diffusion:

  • The passive movement of dissolved particles (solutes) across a semipermeable membrane (dialyzer membrane fibers in hemodialysis; peritoneal membrane in peritoneal dialysis) from an area of higher solute concentration to an area of lower solute concentration.
  • Molecules transported primarily via diffusion include urea, creatinine, electrolytes, and dialyzable drugs.

• Osmosis:

  • The movement of fluid across a semipermeable membrane from an area of lower solute concentration to an area of higher solute concentration, continuing until osmotic equilibrium is approached.

• Ultrafiltration (UF):

  • The process of forcing fluid across a semipermeable membrane by utilizing a mechanical pressure gradient comprising both positive pressure from the blood compartment and negative pressure applied from the dialysate compartment.

Fluid Management, Vascular Refill, and Ultrafiltration Calculations

• Body Fluid Compartments:

  • Intracellular Compartment: Fluid residing inside the individual cells.
  • Extracellular Compartment: Fluid residing outside the cells; excessive accumulation manifests clinically as edema.
  • Interstitial Compartment: Fluid situated specifically in the spaces between tissue cells.
  • Intravascular Compartment: Fluid contained within the blood vessels (plasma).

• Vascular Refill Dynamics:

  • During hemodialysis, fluid is removed exclusively from the intravascular space.
  • During and following treatment, fluid shifts from the intracellular and interstitial compartments into the intravascular space to replenish circulating volume, a physiologic mechanism termed vascular refill.
  • If the ultrafiltration rate ($\text{UFR}$) exceeds the physiological rate of vascular refill, or if total fluid removal exceeds fluid overload, the intravascular volume drops abruptly, precipitating intradialytic hypotension, muscle cramping, and cardiac compromise.

• Estimated Dry Weight (EDW):

  • The physician-prescribed baseline weight representing the patient's weight without excess fluid volume.
  • Must be reassessed at regular intervals to maintain fluid balance and prevent cardiovascular pathology.
  • Signs and Symptoms of an EDW set too high (insufficient fluid removal): Hypertension, persistent headaches, shortness of breath, bilateral lung crackles at the bases, peripheral edema, and distended neck veins. The nurse must report these findings to the physician, and a decrease in the ordered EDW is expected.
  • Signs and Symptoms of an EDW set too low (excessive fluid removal): Dizziness, nausea, vomiting, intradialytic hypotension, painful muscle cramps, and profound post-treatment fatigue.

• Fluid Removal Calculations (Reference Case):

  • Baseline Clinical Data:
    • $\text{Patient EDW} = 74.0\,\text{kg}$
    • $\text{Post-treatment Weight Last Treatment} = 73.8\,\text{kg}$
    • $\text{Pre-treatment Weight Today} = 77.2\,\text{kg}$
    • $\text{Prescribed Treatment Time} = 4.25\,\text{hours}$
    • $\text{Prime and Rinseback Volume} = 500\,\text{mL}$
  • Unit Conversions:
    • $\text{Prime and Rinseback in kg} = \frac{500\,\text{mL}}{1000} = 0.5\,\text{kg}$
    • $\text{Target Weight in kg to UF Goal in mL} = \text{Target Weight (kg)} \times 1000$
  • Weight Gained Calculation:
    • $\text{Weight Gained} = \text{Today's Pre-weight} - \text{Last Post-weight}$
    • $\text{Weight Gained} = 77.2\,\text{kg} - 73.8\,\text{kg} = 3.4\,\text{kg}$
    • Clinical Rule: Weight gains exceeding $4.0\,\text{kg}$ must be reported to the RN for assessment prior to treatment initiation.
  • Available Weight Calculation:
    • $\text{Available Weight} = \text{Today's Pre-weight} - \text{EDW}$
    • $\text{Available Weight} = 77.2\,\text{kg} - 74.0\,\text{kg} = 3.2\,\text{kg}$
    • Represents the total volume of accumulated patient fluid available for removal during the treatment.
  • Target Weight (TW) and Ultrafiltration (UF) Goal Calculation:
    • $\text{Target Weight} = \text{Available Weight} + \text{Prime and Rinseback Volume}$
    • $\text{Target Weight} = 3.2\,\text{kg} + 0.5\,\text{kg} = 3.7\,\text{kg}$
    • $\text{UF Goal} = 3.7\,\text{kg} \times 1000 = 3700\,\text{mL}$
  • Ultrafiltration Rate ($\text{UFR}$) Calculation ($\text{mL/kg/hr}$):
    • $\text{Fluid to Remove per kg} = \frac{\text{UF Goal}}{\text{EDW}} = \frac{3700\,\text{mL}}{74.0\,\text{kg}} = 50\,\text{mL/kg}$
    • $\text{UFR} = \frac{50\,\text{mL/kg}}{4.25\,\text{hours}} = 11.76\,\text{mL/kg/hr}$
    • Clinical Rule: The PCT must immediately report to the RN if the calculated $\text{UFR}$ exceeds $13\,\text{mL/kg/hr}$.

Dialysis Adequacy, Kinetic Clearance, and Treatment Factors

• Clearance Definition:

  • The volume of blood cleared completely of a specific solute in one minute, serving as the quantitative metric of dialysis adequacy.

• Adequacy Benchmarks:

  • Single Pool Kt/V ($\text{spKt/V}$): Measures total dialysis delivered at treatment completion from a single body fluid compartment (the intravascular space).
  • Clearance Target: Minimum delivered $\text{spKt/V}$ target is $1.4$.
  • Blood Urea Nitrogen ($\text{BUN}$): Assessed pre-treatment and post-treatment to quantify urea kinetic clearance.

• On-Line Clearance (OLC) and KECN:

  • $\text{KECN}$: Clearance Effective by Conductivity of Sodium ($Na^+$).
  • Physiological Basis: Sodium clearance is measured continuously via conductivity fluctuations during the OLC test. Because sodium and urea share similar molecular weights and transport dynamics, sodium clearance mirrors urea clearance.
  • Declining $\text{KECN}$ Values: A steady downward trend in sequential $\text{KECN}$ tests indicates falling dialyzer solute clearance. Root causes include fiber clotting (due to improper heparin dosing or substandard priming), drops in blood flow rate ($\text{BFR}$) from access complications, or systemic hypotension. Downward trends require clinical investigation, corrective action, documentation, and adherence to the yellow algorithm.

• Prescription Determinants of Adequacy:

  • Treatment Time: Prescribed duration must be maintained. RNs assess reasons for patient requests to shorten treatments, promote adherence, and instruct on the risks of shortened or skipped sessions.
  • Blood Flow Rate ($\text{BFR}$): Prescribed $\text{BFR}$ directly governs dialyzer perfusion. Staff must document the specific clinical rationale whenever prescribed $\text{BFR}$ cannot be achieved due to access compromise.
  • Dialysate Flow Rate ($\text{DFR}$) and Countercurrent Geometry: Flowing blood and dialysate in opposite directions (countercurrent flow) across the hollow fibers maximizes the concentration gradient along the length of the dialyzer, optimizing diffusive clearance.
  • Dialyzer Surface Area: Clotted hollow fibers reduce effective surface area and impair clearance. Priming at a pump speed of $150\,\text{mL/min}$ eliminates air pockets, minimizing clot formation. Maintaining appropriate heparin anticoagulation and swiftly resolving machine alarms reduces stagnant blood flow and fiber clotting.

• Standardized Post-BUN Blood Sampling Protocol:

  • Pre-treatment and post-treatment $\text{BUN}$ samples must be obtained on the same treatment day.
  • Post-treatment sample must be drawn prior to blood rinseback.
  • Step 1: Upon treatment completion, turn off the dialysate flow rate ($\text{DFR}$) and ultrafiltration ($\text{UF}$).
  • Step 2: Reduce the blood pump flow rate to $100\,\text{mL/min}$.
  • Step 3: Wait precisely $15\,\text{seconds}$ (exact timing is critical to prevent access recirculation and clearance artifacts).
  • Step 4: Stop the blood pump.
  • Step 5: Disinfect the arterial bloodline sampling port with an alcohol prep pad.
  • Step 6: Insert a vacutainer needle device into the port and engage the collection tube to draw the blood sample.
  • Step 7: Invert the collection tube gently $5\text{--}10\,\text{times}$ and position it upright in a test tube rack. Do not place tubes on top of the dialysis machine (heat alters test stability).
  • Step 8: Turn the dialysate flow rate back on and perform rinseback per standard operating procedure.

• Vascular Access Flow Monitoring Thresholds:

  • Report to the nephrologist if arteriovenous graft ($\text{AVG}$) flow drops below $600\,\text{mL/min}$.
  • Report to the nephrologist if arteriovenous fistula ($\text{AVF}$) flow drops below $400\,\text{mL/min}$.
  • Report to the nephrologist if access flow drops by $25\%$ or greater from baseline.
  • Report to the nephrologist if arteriovenous fistula ($\text{AVF}$) flow exceeds $2000\,\text{mL/min}$.

Clinical Laboratory Monitoring and Management

• Serum Albumin:

  • Reference Target: $> 4.0\,\text{g/dL}$.
  • Clinical Relevance: Evaluates visceral protein intake. Malnutrition correlates with elevated morbidity and mortality. Hypoalbuminemia may also reflect active systemic inflammation or infection.
  • Interventions: Promote high-biological-value protein consumption; collaborate with the Interdisciplinary Team (IDT). If levels drop below $3.5\,\text{g/dL}$, administer oral nutritional supplements (e.g., Nepro®) during clinic treatments. RN assesses for underlying infectious processes.

• Serum Potassium ($K^+$):

  • Reference Target: $3.5\text{--}5.0\,\text{mEq/L}$.
  • Clinical Relevance: Governs neuromuscular and myocardial excitability. Hyperkalemia results from high dietary intake, gastrointestinal bleeding, hemolysis, or blood transfusions, precipitating muscle weakness, lethal cardiac arrhythmias, and cardiac arrest. Hypokalemia from vomiting or diarrhea similarly triggers arrhythmias.
  • Interventions: Reinforce a low-potassium diet ($2000\,\text{mg/day}$ per KDOQI guidelines); avoid potassium chloride salt substitutes; evaluate cardiac rhythm irregularities; adjust dialysate potassium ($K^+$) bath concentration per physician prescription.

• Serum Sodium ($Na^+$):

  • Reference Target: $135\text{--}145\,\text{mEq/L}$.
  • Clinical Relevance: Principal extracellular cation determining osmolarity. Hypernatremia drives osmotic thirst, resulting in excessive interdialytic weight gains (IDWG).
  • Interventions: Review sodium dialysate setting; assess dietary intake of processed foods; coordinate with IDT; notify physician.

• Serum Phosphorus ($PO_4$):

  • Reference Target: $3.0\text{--}5.5\,\text{g/dL}$ (clinical standard $3.0\text{--}5.5\,\text{mg/dL}$).
  • Clinical Relevance: Works in conjunction with calcium for skeletal mineralization. Sustained hyperphosphatemia produces secondary hyperparathyroidism, renal osteodystrophy, and extraosseous calcification. Patient mortality escalates significantly when serum levels exceed $7\,\text{g/dL}$.
  • Interventions: Engage IDT; assess adherence to dietary restrictions and phosphate binder schedules; notify physician of abnormal values.

• Serum Calcium ($Ca^{2+}$):

  • Reference Target: $8.5\text{--}10\,\text{g/dL}$ (clinical standard $8.5\text{--}10\,\text{mg/dL}$).
  • Clinical Relevance: Regulates neuromuscular transmission and muscle contraction. In hypocalcemia, parathyroid hormone mobilizes calcium from skeletal reserves. Hypercalcemia exceeding $12\,\text{g/dL}$ causes mental confusion and progressive coma.
  • Interventions: When hypercalcemia is present, Renvela® (sevelamer carbonate) is the preferred phosphate binder; evaluate vitamin D analogs and calcium-based binders; notify physician.

• Hemoglobin (Hgb):

  • Reference Target: $10\text{--}11\,\text{g/dL}$.
  • Clinical Relevance: Quantifies oxygen-carrying capacity. Depressed levels suggest hyporesponsiveness to Erythropoiesis-Stimulating Agents (ESA) or secondary comorbidities.
  • Interventions: If Hgb decreases by $> 1.0\,\text{g/dL}$ within a $2\,\text{week}$ timeframe or falls below $8.0\,\text{g/dL}$, notify physician, assess for gastrointestinal bleeding, and adjust ESA and iron orders. For persistent hyporesponsiveness, investigate occult infection, inflammation, or malignancy.

• White Blood Cell Count (WBC):

  • Reference Target: $5.0\text{--}10.0 \times 10^3/\mu\text{L}$.
  • Clinical Relevance: Leukocytes mediating immune defense. Elevations indicate systemic infection or inflammatory states. Decreases stem from bone marrow suppression, nutritional deficits, autoimmune pathology, or myelodysplastic syndromes.

• Transferrin Saturation (TSAT):

  • Reference Target: $20\text{--}50\%$.
  • Clinical Relevance: Quantifies circulating iron available to support erythropoiesis in the bone marrow. Levels decrease during inflammation or infection and demonstrate an inverse relationship with ferritin. Absolute iron deficiency is defined as a TSAT below $20\%$ in conjunction with a ferritin below $200\,\text{mg/dL}$.
  • Interventions: Avoid drawing blood samples while intravenous iron infusions are actively running (yields falsely elevated values). Follow the anemia hyporesponsiveness algorithm, assess for systemic inflammation, verify iron administration records, and notify the physician.

• Serum Ferritin:

  • Reference Target: $100\text{--}800\,\text{mg/dL}$ (clinical standard $100\text{--}800\,\text{ng/mL}$).
  • Clinical Relevance: Measures iron storage reserves inside hepatocytes, bone marrow, and the spleen. Acts as an acute-phase reactant; levels increase during infectious episodes, active inflammation, hepatic disease, and malignant states.
  • Interventions: Monitor values closely during inflammatory episodes; assess iron stores per the clinical anemia management protocol.

• Serum Glucose (Blood Sugar):

  • Fasting Reference Range: $70\text{--}105\,\text{mg/dL}$.
  • Hypoglycemia: Subnormal glucose triggered by excess circulating insulin or inadequate caloric intake. Symptoms: faintness, diaphoresis (perspiration), visual disturbances (diplopia/double vision), irritability, and hunger. Interventions: test blood glucose immediately; treat with oral carbohydrates or intravenous dextrose ($D_{50}$) per physician order; if unresponsive or comatose, activate emergency medical services (EMS).
  • Hyperglycemia: Elevated glucose reflecting uncontrolled diabetes mellitus. Notify physician for medication titration.

• Hemoglobin A1C ($\text{HbA1c}$):

  • Target: $< 7\%$ based on KDOQI clinical guidelines.
  • Clinical Relevance: Quantifies the percentage of hemoglobin bound to glucose (glycated), providing a moving average of glycemic regulation over the preceding $2\text{--}3\,\text{months}$. Testing interval varies from quarterly to annually based on diabetes classification and medical regimen.

Vascular Access Modalities: Types, Cannulation, and Assessment

• Arteriovenous Fistula (AVF) — Preferred Access:

  • Surgical Construction: Surgical connection (single surgical anastomosis) directly linking a native artery to an adjacent native vein.
  • Advantages: Constructed entirely from autologous tissue (no synthetic graft material; no risk of allergic response); demonstrates the longest functional longevity; has the lowest incidence of thrombosis and infection; vessel walls seal and heal readily between cannulations.
  • Disadvantages: Requires extended maturation time (generally $1\text{--}4\,\text{months}$); maturation failure may occur; can be difficult to cannulate; requires mandatory tourniquet application during cannulation; blood flow rates must be limited if immature (lowering adequacy); collateral veins may divert flow; surgical creation is challenging in patients with advanced diabetes, hypertension, peripheral vascular disease, and severe obesity; can develop into large, cosmetically unsightly aneurysmal dilatations over time.

• Arteriovenous Graft (AVG):

  • Surgical Construction: Implantation of an artificial, synthetic conduit (e.g., PTFE) tunneling under the skin to bridge an artery and a vein.
  • Advantages: Offers a large, accessible cannulation surface area; easier to palpate and cannulate; short postoperative maturation/healing interval; available in varied configurations and configurations suitable for multiple anatomical locations; easy to surgically construct, revise, and thrombectomize.
  • Disadvantages: Higher incidence of vascular stenosis and thrombosis; higher infection rates than AVFs; prolonged bleeding following needle withdrawal (synthetic materials do not physiologically contract); cannulation puncture sites do not heal biologically, requiring rigorous site rotation; requires surgical replacement over time; associated with higher patient mortality rates than AVFs.

• Central Venous Catheter (CVC):

  • Construction: Dual-lumen catheter surgically introduced into a large central thoracic vein (internal jugular, subclavian, or femoral).
  • Advantages: Ready for immediate clinical use following radiographic verification of tip placement; serves as the final or sole option for patients with depleted peripheral vasculature; requires no cannulation or post-treatment puncture hemostasis.
  • Disadvantages: High risk for systemic catheter-related bacteremia and luminal thrombosis; elevated potential for air embolism; limited blood flow rates ($\text{BFR}$) necessitating longer treatment durations to achieve adequacy; extended use frequently causes central vein stenosis; reversing line connections increases access recirculation and reduces dialytic clearance; associated with higher mortality rates than AVFs and AVGs.

• Physical Examination of AVFs and AVGs:

  • Look: Inspect skin color, integrity of surgical incisions, signs of infection (erythema, localized edema, purulent exudate), condition of prior cannulation sites, and perform side-by-side anatomical comparisons with the non-access arm.
  • Listen: Auscultate the full length of the access with a stethoscope to confirm the presence of an audible bruit—a continuous, low-pitched whooshing sound that is naturally louder toward the arterial anastomosis.
  • Feel: Palpate the entire tract of the access to feel for a thrill (a continuous vibrating buzz); evaluate the pulse (slight beating sensation akin to a heartbeat); assess skin temperature (localized warmth indicates infection; coolness indicates arterial steal or impaired perfusion).

• Central Venous Catheter Monitoring:

  • Routinely inspect and report any erythema, tenderness, swelling, or drainage at the catheter exit site.
  • Report resistance, poor aspiration, or sluggish flushing of catheter lumens.
  • Notify the RN of difficulties encountered during treatment initiation for assessment and nephrologist communication.

• Cannulation Principles:

  • Tourniquet Application: Mandatory for cannulating every arteriovenous fistula to engorge the vessel.
  • Needle Direction: Venous needles must always be positioned pointing in the direction of blood flow (antegrade). Arterial needles may be oriented facing either with the flow (antegrade) or against the flow (retrograde).
  • No Flipping: Flipping cannulation needles tears the intimal lining of the vessel and is strictly prohibited; modern fistula needles feature back-eyes to preserve flow without lodging against the inner vessel wall.
  • Needle Spacing: Position needle tips a minimum of $2\,\text{inches}$ apart to prevent access recirculation and subsequent drops in dialytic clearance.
  • Anastomosis Clearance: Needles must be inserted at least $1.5\,\text{inches}$ away from the surgical anastomosis.

• Needle Withdrawal and Post-Treatment Hemostasis:

  • Safety Device: Fully engage the active needle safety mechanism simultaneously with needle withdrawal from the access.
  • Single Withdrawal: Withdraw needles one at a time.
  • Protective Barriers: Patients holding their own access sites must wear gloves.
  • Mechanical Clamps: Use of fistula clamps requires an explicit physician order; never apply more than one clamp simultaneously to avoid vessel occlusion and thrombus development.
  • Prolonged Bleeding: Report bleeding that exceeds $20\,\text{minutes}$ post-removal to the RN.
  • Post-Hemostasis Verification: Palpate and confirm the presence of a thrill immediately after achieving complete hemostasis.

Vascular Access Complications and Interventions

• Access Infection:

  • Clinical Presentation: Localized erythema (redness), warmth, edema, and purulent drainage.
  • Clinical Actions: Do not cannulate in or adjacent to the affected site (prevents seeding bacteria into systemic circulation and causing sepsis). Thoroughly prep skin working outward in a circular motion. Instruct patient to wash the access arm thoroughly with soap and water prior to sitting in the dialysis station.

• Aneurysm and Pseudoaneurysm:

  • Clinical Presentation: Weakened, localized ballooning of the vascular wall secondary to repeated cannulations in the same localized area ("one-site cannulation"); features thin, shiny overlying skin and poor site healing.
  • Clinical Actions: Never cannulate into aneurysmal bulges (high risk of fatal exsanguination). Educate the patient that staff will avoid cannulating bulges and rotate needle sites.

• Vascular Access Thrombosis:

  • Clinical Presentation: Complete absence of a palpable thrill and audible bruit.
  • Etiological Triggers: Excessive digital pressure during post-treatment hemostasis, wearing tight clothing or restrictive jewelry, holding two puncture sites simultaneously, improper use of mechanical clamps, sleeping on the access arm, profound dehydration, and intradialytic hypotension.
  • Clinical Actions: Do not attempt to cannulate. Arrange immediate declotting intervention. If mechanical clamps are ordered, use only one at a time.

• Needle Infiltration:

  • Clinical Presentation: Sudden localized pain, swelling, rapid hematoma formation, and abrupt alterations in arterial pressure ($\text{AP}$) or venous pressure ($\text{VP}$).
  • Clinical Actions: If infiltration occurs during treatment, immediately stop the blood pump. If the venous line infiltrates, cannulate above (proximal to) the site of infiltration. Adhere to needle gauge and pump speed guidelines when cannulating new fistulas. Apply intermittent ice packs to the site for the initial $24\,\text{hours}$.

• Prolonged Post-Dialysis Bleeding:

  • Clinical Presentation: Cannulation sites continue to bleed $20\,\text{minutes}$ or longer after needle withdrawal.
  • Clinical Actions: Report finding to the RN and notify the physician. Indicates developing outflow venous stenosis proximal to the cannulation site; schedule diagnostic imaging to evaluate and correct the anatomical narrowing.

• Pneumothorax:

  • Clinical Presentation: Sudden onset of chest pain, acute shortness of breath (dyspnea), and decreased or completely absent unilateral breath sounds on auscultation.
  • Pathophysiology: Complication associated with central venous catheter insertion where the needle or introducer punctures the lung apex, allowing air into the pleural space.
  • Clinical Actions: Review radiographic verification of catheter placement prior to initiating the patient's first hemodialysis treatment via a newly placed CVC. If respiratory distress or absent breath sounds arise, hold treatment, immediately contact the physician, and if occurring during therapy, immediately stop treatment.

• Patient Education for AVF/AVG Clot Prevention:

  • Never wear tight-fitting sleeves, restrictive clothing, watches, or tight jewelry on the access arm.
  • Avoid sleeping with body weight resting on the access arm.
  • Do not permit venipunctures, peripheral intravenous line placements, or blood pressure cuff inflations on the access limb. (Clinical staff must examine both arms of newly admitted patients for vascular accesses prior to measuring blood pressure).
  • Do not carry heavy objects, packages, or bags across the access extremity.
  • Instruct the patient to palpate the thrill daily and report any softening or loss of vibration immediately.

Infection Control, Sharps Disposal, and Environmental Disinfection

• Personal Protective Equipment (PPE) Matrix:

  • Gloves (Mandatory for all clinical contact; change after every individual patient contact):
    • Touching any part of the dialysis machine or station equipment while a patient is connected.
    • Setting up the hemodialysis machine.
    • Connecting and priming the dialyzer.
    • Handling collected blood tubes.
    • Handling potentially contaminated surfaces or equipment.
    • Handling infectious clinical waste.
    • Actual or potential contact with blood, body fluids, mucous membranes, or biological tissues.
    • Stripping the machine and extracorporeal lines following treatment.
    • Initiating hemodialysis or peritoneal dialysis.
    • Terminating hemodialysis or peritoneal dialysis.
    • Applying manual pressure to needle puncture sites.
    • Performing venipuncture or any invasive vascular access procedure.
  • Full Face Shield or Mask combined with Protective Eyewear (Full side shields required):
    • Connecting and priming the dialyzer.
    • Handling collected blood tubes.
    • Handling infectious clinical waste.
    • Actual or potential contact with blood, body fluids, mucous membranes, or non-intact tissue.
    • Stripping the machine and extracorporeal circuit after treatment.
    • Initiating hemodialysis or peritoneal dialysis.
    • Terminating hemodialysis or peritoneal dialysis.
    • Applying digital pressure to needle cannulation sites.
    • Performing venipunctures or access interventions.
  • Fluid-Resistant Gown:
    • Connecting and priming the dialyzer.
    • Handling infectious clinical waste.
    • Actual or potential contact with blood, body fluids, mucous membranes, or tissues.
    • Stripping the machine and extracorporeal circuit post-treatment.
    • Initiating hemodialysis or peritoneal dialysis.
    • Terminating hemodialysis or peritoneal dialysis.
    • Holding cannulation sites.
    • Performing venipunctures or access manipulations.

• Safe Handling and Disposal of Sharps:

  • Designated Sharps Container Items: Broken glassware, medication ampules, and all syringes coupled with needles (both used and clean).
  • Glass Cleanup Rule: Pick up broken glass exclusively using a broom and dustpan; never pick up broken glass with bare hands.
  • Container Replacement Threshold: Sharps containers must be closed, locked, and replaced when filled to between $2/3$ and $3/4$ capacity.
  • Handling Rule: Never shake or agitate sharps containers to condense internal contents.

• Bleach Disinfection Protocols:

  • General Requirements: Fresh solutions must be prepared daily in opaque containers equipped with lids (to prevent chlorine gas dissipation and potency loss) and labeled with solution concentration, preparation date, time, and preparer initials.
  • $1:100\ (1\%)$ Bleach Solution:
    • Formulation: $1\,\text{part bleach to } 99\,\text{parts water}$ (e.g., $60\,\text{mL}$ bleach added to $5940\,\text{mL}$ tap water).
    • Indications: Routine surface disinfection of all dialysis stations and equipment; soaking reusable vascular clamps in an open configuration for $10\,\text{minutes}$; managing small blood spills of less than $10\,\text{mL}$.
    • Routine Disinfection Technique (no visible blood): Don PPE, thoroughly wipe all surfaces with a cloth saturated in $1:100$ bleach until glisteningly wet, allow to air dry completely, doff gloves, and perform hand hygiene.
    • Small Blood Spills ($< 10\,\text{mL}$): Initial cleaning and disinfection using a $1:100$ bleach-soaked cloth, followed immediately by a second disinfection using a fresh $1:100$ bleach-soaked cloth.
  • $1:10\ (10\%)$ Bleach Solution:
    • Formulation: $1\,\text{part bleach to } 9\,\text{parts water}$ (e.g., $60\,\text{mL}$ bleach added to $540\,\text{mL}$ tap water).
    • Indications: Dedicated solely to blood spills measuring greater than $10\,\text{mL}$. Not permitted for routine surface cleaning or routine equipment disinfection.
    • Large Blood Spill Procedure ($> 10\,\text{mL}$): Don full PPE; cover the spill with absorbent materials; wipe up gross contamination with a $1:10$ bleach-soaked cloth; discard soiled towels and gloves in biohazard receptacle; perform hand hygiene; don clean gloves; perform a secondary disinfection of the surface using a $1:100$ bleach-soaked cloth; allow surface to air dry; doff gloves; perform hand hygiene.

Dialysis Isolation Protocols and Transmission Precautions

• Universal Dialysis Precautions:

  • Applied to all patients across the dialysis setting.
  • Treat all patients, blood, body fluids, tissues, sharps, used dialyzers, and clinical equipment as infectious and contaminated.

• Airborne Precautions — Mycobacterium tuberculosis (TB):

  • Patients with suspected or active pulmonary tuberculosis are prohibited from receiving treatment in outpatient dialysis clinics.
  • If a patient presents with suspected TB, have them don a surgical mask immediately, contact the physician, and transfer them to an acute inpatient hospital setting equipped with airborne negative-pressure isolation rooms.

• Droplet Precautions — Influenza:

  • Staff and patients wear surgical masks.
  • Maintain spatial separation of at least $3\,\text{feet}$ between patient treatment stations.

• Contact Precautions — MRSA and VRE:

  • Dedicate station equipment (blood pressure cuff, stethoscope, tourniquet) exclusively to the patient.
  • Staff must wear a dedicated gown during direct interactions.
  • Cohort patients with identical multidrug-resistant organisms in designated areas if feasible.
  • Dialysis in an isolation room is permissible only if no patients with active Hepatitis B are currently assigned to that room.

• Hepatitis B Virus (HBV) Isolation Protocol:

  • Applies to all patients testing positive or reactive for Hepatitis B Surface Antigen (HBsAg).
  • Pathogen Dynamics: HBV is transmitted via blood and bodily fluids and remains viable and virulent on dry environmental surfaces for at least $7\,\text{days}$.
  • Facility Requirements: Treatment must occur in a dedicated, negative-pressure isolation room separated from the general patient floor, utilizing dedicated equipment, blood pressure cuffs, and supply stocks.
  • Documentation Mandate: Staff must complete all computer charting inside the isolation room wearing a clean, fresh pair of gloves (donned after removing soiled treatment gloves and performing hand hygiene).
  • Buffer Zone Configuration: The patient stations located immediately outside the HBV isolation room door must serve as an immunological buffer zone populated exclusively by patients confirmed immune to HBV (defined as an Anti-HBs titer of $10\,\text{mIU/mL}$ or greater).

Patient Safety Events, Classification, and Disaster Preparedness

• Patient Safety Terminology (AHRQ):

  • Near Miss: An operational hazard or clinical variance that did not reach or harm the patient, but possessed the clear capacity to do so.
  • Safety Event: An incident resulting in mild to moderate patient clinical harm that necessitates clinical monitoring, secondary intervention, or supportive care.
  • Serious Safety Event: An event producing severe, permanent, or life-threatening harm that mandates lifesaving clinical interventions, emergency hospitalization, or results in death.
  • Sentinel Event (Inpatient Services / IPS only): A subset of serious safety events resulting in catastrophic harm, permanent injury, severe temporary impairment, or death.

• Mandatory Reportable Incidents:

  • Abusive or violent patient behavior.
  • Suspected air embolism.
  • Extracorporeal blood loss or vascular disconnects.
  • Administration of an incorrect blood transfusion unit.
  • Cardiopulmonary arrest (following immediate emergency care, the dialysis machine must be removed from the floor and quarantined for biomedical testing).
  • Clinical laboratory errors, including missed blood draws.
  • Patient falls.
  • Treatment order variances, such as using an incorrect dialyzer model or improper dialysate bath concentrate (requires immediate notification of the RN).
  • Medication administration errors or omissions.

• Safety Documentation Platforms:

  • Incenter and Home Therapies: Documented via the Patient Safety Data Entry Application (formerly the Adverse Event Data Entry Site) and reviewed during monthly Quality Assessment and Performance Improvement (QAPI) EQUIP Patient Safety Events Workbook trending reviews.
  • Inpatient Services (IPS): Documented in the ACES system and evaluated during internal inpatient QAPI committee meetings.

• Disaster Preparedness and Hazard Vulnerability Analysis (HVA):

  • The clinic Interdisciplinary Team, directed by the Director of Operations (DO), must evaluate and execute the Hazard Vulnerability Assessment spreadsheet annually.
  • The DO ensures that clinics in close geographic proximity maintain standardized, aligned HVAs.
  • Assess geographic vulnerabilities, regional natural disaster risks, and proximity to hazardous infrastructure (nuclear plants, chemical refineries, industrial complexes, and commercial airports).
  • Potential Disasters: Gas leaks, chemical spills, pandemics, bomb threats, sabotage/terrorism, active shooter events, fires, tornadoes, earthquakes, hurricanes, winter blizzards, floods, tsunamis, civil disturbances, catastrophic power failures, and municipal water service interruptions.

Pharmacotherapy in Renal Replacement Therapy

• Pharmacokinetic Considerations in End-Stage Renal Disease:

  • Because the renal system is the primary excretory pathway for pharmaceutical compounds and active metabolites, impaired clearance leads to drug accumulation, heightened systemic toxicity, prolonged half-lives, enhanced potency, and increased frequency of adverse drug reactions.

• Six Rights of Medication Administration:

  • Right Drug, Right Dose, Right Route, Right Time, Right Patient, and Right Documentation.

• Aseptic Medication Preparation Rules:

  • Prepare all medications in a designated clean medication preparation area.
  • Vigorously scrub the rubber vial stopper with an alcohol prep pad before every puncture.
  • Mobile medication carts are prohibited on the treatment floor.
  • Do not carry medications between patient stations.
  • Never place medication vials, syringes, or ampules on top of the dialysis machine.
  • Medications may be pre-drawn up to a maximum of $4\,\text{hours}$ prior to administration (unless state regulations prescribe a shorter duration); syringes must be labeled and stored under the direct control of the preparer, in a locked storage area, or inside a medication refrigerator.

• Formulary Medication Reference:

  • Topical Anesthetics — Emla Cream® (Lidocaine $2.5\%$ / Prilocaine $2.5\%$):
    • Indication: Alleviates venipuncture pain during needle cannulation.
    • Considerations: Must be applied to intact skin $1\,\text{hour}$ prior to cannulation; aggressive application causes cutaneous vasodilation and subsequent hypotension.
  • Cardiac Glycosides / Anti-arrhythmics — Digoxin (Digtek, Digox, Lanoxicaps, Lanoxin):
    • Indication: Management of congestive heart failure and atrial fibrillation.
    • Considerations: High risk of digitalis toxicity in renal failure; can produce severe, life-threatening bradycardia; hypokalemia dramatically potentiates toxicity; serum potassium ($K^+$) levels must be monitored.
  • Anti-anginals — Nitroglycerin and Oxygen ($O_2$):
    • Indication: Relief of intradialytic acute chest pain (angina).
    • Considerations: Nitroglycerin induces systemic vasodilation and profound hypotension; transdermal nitroglycerin patches must be removed prior to cardioversion or defibrillation to prevent electrical arcing and burns. Oxygen is classified as a drug and must be initiated by the RN. Worsening angina or pain unresponsive to oxygen indicates acute myocardial infarction—terminate dialysis and notify the physician.
  • Antibiotics — Cefazolin (Ancef® / Kefzon), Ceftazidime (Tazicef / Fortaz), Vancomycin, Gentamicin:
    • Indication: Treatment of vascular access and systemic bacterial infections.
    • Considerations: Certain agents must be administered during the final minutes or at the conclusion of treatment to prevent dialytic clearance. Anaphylactic reactions can occur at any time. Rapid infusion of vancomycin causes hypotension and "red man syndrome"; aminoglycosides (gentamicin) carry severe ototoxicity risks.
  • Anticoagulants — Heparin Sodium and Sodium Citrate:
    • Indication: Heparin prevents clotting within the extracorporeal circuit; 4% sodium citrate serves as a regional anticoagulant lock solution for central venous catheters.
    • Contraindications: Documented heparin allergy/HIT, active internal or external hemorrhage, impending surgery, recent invasive surgical or dental procedures, and recent falls (due to the risk of expanding subdural hematomas). Heparin is contraindicated in uremic pericarditis due to the risk of hemopericardium and fatal cardiac tamponade.
  • Antipruritics — Diphenhydramine (Benadryl) and Hydroxyzine (Vistaril®):
    • Indication: Relieves intradialytic itching caused by hyperphosphatemia or uremic toxin retention.
    • Considerations: Causes central nervous system depression, drowsiness, dizziness, muscle weakness, and ataxia.
  • Erythropoiesis-Stimulating Agents (ESAs) — Epoetin alfa (Epogen), Darbepoetin alfa (Aranesp®), Methoxy polyethylene glycol-epoetin beta (Micera®):
    • Indication: Corrects chronic anemia by stimulating erythroid progenitor cells in bone marrow.
    • Considerations: Always evaluate pre-treatment hemoglobin values prior to administration to ensure levels remain within the target range ($10\text{--}11\,\text{g/dL}$).
  • Intravenous Iron Preparations — Iron Sucrose (Venofer) and Sodium Ferric Gluconate (Ferrlecit):
    • Indication: Corrects absolute and functional iron deficiencies to support erythropoiesis.
    • Considerations: Rapid infusion can trigger cardiovascular collapse and anaphylactoid shock; never infuse at rates exceeding $100\,\text{mg}$ over $2\,\text{minutes}$. Venofer must be prescribed in increments of $50\,\text{mg}$; dosing frequency should be modulated to match cumulative targets (e.g., $50\,\text{mg}$ every other week rather than $25\,\text{mg}$ weekly to achieve a monthly target of $100\,\text{mg}$). Monitor for pruritus, hypotension, and hypersensitivity.
  • Phosphate Binders — Calcium Acetate (Phos-lo), Sevelamer Hydrochloride (Renagel®), Calcium Carbonate (Tums):
    • Indication: Binds dietary phosphorus in the gastrointestinal tract to prevent systemic absorption.
    • Considerations: Must be ingested directly with meals and snacks to be therapeutically active; must be spaced apart from other oral medications by $2\text{--}4\,\text{hours}$ to prevent drug-binding interactions.
  • Water-Soluble Vitamins — Nephro-vite, Nephro-caps, Multivitamins, Pyridoxine ($B_6$), Cyanocobalamin ($B_{12}$), Folic Acid:
    • Indication: Replenishes essential water-soluble vitamins cleared through the dialyzer membrane.
    • Considerations: Must be administered after completion of the hemodialysis treatment to avoid dialytic removal.
  • Vitamin D Analogs and Calcimimetics — Paricalcitol (Zemplar®), Doxercalciferol (Hecterol), Calcitriol, Cinacalcet (Sensipar):
    • Indication: Suppresses parathyroid hormone secretion in secondary hyperparathyroidism.
    • Considerations: Vitamin D analogs promote enteric calcium absorption and can trigger hypercalcemia.
  • Over-the-Counter (OTC) Products, Herbals, and Heartburn Formulations:
    • All non-prescription supplements, antacids, and botanicals must be approved by the nephrologist due to toxic accumulation risks (e.g., magnesium, aluminum) and drug interactions.

Hemodialysis Machine Mechanics, Extracorporeal Circuit, and Alarm Systems

• Extracorporeal Blood Delivery Circuit:

  • Composed of the arterial bloodline, blood pump segment, dialyzer blood compartment, venous drip chamber, and venous return bloodline.
  • Lines are primed with sterile $0.9\%$ normal saline to evacuate chemical sterilants and residual air.
  • Residual micro air bubbles entering the dialyzer cause platelet aggregation, fibrin deposition, and fiber clotting; macroscopic air passing to the patient triggers venous air embolism.
  • Aseptic Integrity: If bloodline ends are dropped onto the floor or submerged in prime waste buckets without protective caps, the bloodlines are contaminated and must be discarded.

• Pre-Treatment Diagnostics:

  • Every machine must successfully complete and pass internal Alarm Safety Tests and Pressure Holding Tests ($\text{PHT}$) with fluid-primed bloodlines prior to connecting a patient.

• Comparative Mechanics of Machine Alarm States:

  • Blood-Related Alarms (Impact the Extracorporeal Blood Circuit):
    • Mechanical Response: The blood pump stops; blood ceases circulating through the lines.
    • Dialysis Adequacy Impact: Clearance halts entirely; the Rest Treatment Distance ($\text{RTD}$) adequacy clock stops.
    • Ultrafiltration Impact: Ultrafiltration halts; the $\text{UF}$ countdown clock pauses.
    • Clinical Danger: Stagnant blood inside the dialyzer fibers and bloodlines will clot if the pump remains off.
    • Specific Blood Alarms: Blood Leak, Air Detector, Arterial Pressure ($\text{AP}$), Venous Pressure ($\text{VP}$), and Transmembrane Pressure ($\text{TMP}$).
  • Dialysate-Related Alarms (Impact the Dialysate Circuit):
    • Mechanical Response: The dialysate pathway is diverted into internal bypass; dialysate stops flowing through the dialyzer; the blood pump continues running.
    • Dialysis Adequacy Impact: Solute clearance halts due to dialysate bypass; the $\text{RTD}$ clock pauses; delivered adequacy decreases.
    • Ultrafiltration Impact: Ultrafiltration continues uninterrupted; the $\text{UF}$ clock continues counting down.
    • Specific Dialysate Alarms: High/Low Conductivity and High/Low Temperature.

• Etiology and Management of Common Machine Alarms:

  • Blood Leak Alarm:
    • Pathophysiology: Hollow dialyzer fibers have ruptured internally, allowing patient blood to cross into the non-sterile dialysate compartment, while non-sterile dialysate crosses into the bloodstream.
    • Action: Inspect the dialysate effluent line (red Hansen connector) for visible pink/red discoloration. If gross blood is absent, test the effluent fluid using a chemical blood leak test strip. If the strip tests positive, immediately terminate treatment and do not return the blood to the patient.
  • Air Detector Alarm:
    • Pathophysiology: Acoustic sensors detect microscopic air bubbles or foam in the venous drip chamber line below the level of the filter.
    • Action: The machine snaps the venous line clamp shut and halts the blood pump to prevent an air embolism. Never disarm, mute, or bypass the air detector.
  • Venous Pressure ($\text{VP}$) Alarm:
    • Pathophysiology: Reflects the positive hydrostatic pressure required to return blood into the patient's vascular access. Clinical rule of thumb: $\text{VP}$ is roughly equal to half the blood flow rate ($\frac{1}{2}\,\text{BFR}$).
    • High $\text{VP}$ Causes (occlusion from venous chamber down to access): Kinked venous bloodline, clotted or poorly positioned venous needle, infiltration of the venous cannulation site, central venous stenosis, or thrombus within the venous drip chamber. If clotting forms in the venous chamber, the entire extracorporeal circuit must be replaced.
    • Low $\text{VP}$ Causes: Separation of the bloodline connection, needle dislodgement from the access, or a major drop in blood flow.
  • Arterial Pressure ($\text{AP}$) Alarm:
    • Pathophysiology: Represents the negative pressure (vacuum) generated by the blood pump pulling blood from the vascular access.
    • Exceeding Negative Pressure Limits: Arterial pressure must never become more negative than $-250\,\text{mmHg}$. Severe negative pressure ($< -250\,\text{mmHg}$) induces mechanical shear stress that ruptures red blood cells (hemolysis), releasing toxic intracellular potassium ($K^+$) into the bloodstream, drawing micro-air through fittings, and causing dialyzer clotting.
    • High Negative $\text{AP}$ Causes (resistance between access and pump): Kinks in the arterial line, needle suctioning against the vessel intima, intra-access thrombus, using an undersized needle gauge for a high $\text{BFR}$, or systemic hypotension reducing access perfusion.
  • Transmembrane Pressure ($\text{TMP}$) Alarm:
    • Pathophysiology: Measures the pressure differential across the semipermeable hollow-fiber membrane between the blood compartment and the dialysate compartment required to drive ultrafiltration.
    • Action: As dialyzer fibers clot off with fibrin and cellular debris, higher pressure gradients are required to force fluid across the reduced surface area, causing $\text{TMP}$ to climb.
  • Non-Halting System Alarms:
    • Blood Pressure Monitor Alarm: Emits intermittent audible tones when blood pressure measurements violate programmed limits; the blood pump continues operating.
    • Conductivity Alarm: Out-of-spec dialysate triggers dialysate bypass to protect the patient from hemolysis or crenation; the blood pump continues operating.

• Intradialytic Patient Safety Monitoring Protocols:

  • Safety checks must be performed and charted every $30\,\text{minutes}$ or more frequently as clinically indicated.
  • Vascular access cannulation sites, catheter connections (including the Hemosafe clip affixed across the CVC-bloodline junction), the full extracorporeal circuit, and the patient's face must remain uncovered and visible at all times to detect early signs of hypovolemic shock, unconsciousness, or catastrophic exsanguination.
  • Unresponsive Patients: If a patient appears asleep, fails to respond to verbal prompts, and shows downward-trending blood pressure, wake and evaluate the patient immediately. Report all abnormal findings to the RN.

Water Treatment, Dialysate Composition, and Quality Assurance Testing

• Municipal Water Hazards and Dialysate Toxicity:

  • Tap water used to formulate dialysate contains chemical contaminants, dissolved minerals, bacteria, and toxic chemical additives.
  • Because hemodialysis exposes the patient's blood to large volumes of dialysate across a thin membrane, tap water contaminants will diffuse into the bloodstream, producing systemic toxicity.
  • Municipalities add chlorine (bleach alone) and chloramines (bleach combined with ammonia) as biocides to eradicate waterborne microorganisms.
  • Hemolytic Crisis: Exposure to free chlorine or chloramines causes hemolysis—the lysis and rupture of red blood cell membranes—spilling free hemoglobin and intracellular potassium ($K^+$) into the plasma. Loss of oxygen-carrying capacity causes tissue hypoxia, while acute hyperkalemia precipitates fatal cardiac arrhythmias and death.
  • Granular Activated Carbon (GAC) Tanks: Primary water system components that adsorb and remove free chlorine and chloramines to prevent hemolysis.
  • Microbiological Purity: Hemodialysis water and dialysate are not sterile. Continuous microbiological water monitoring and specialized filtration (such as the Diasafe filter located on the back of the machine) are required to deliver ultrapure dialysate free of bacteria and pyrogenic bacterial endotoxins.

• Physiological Role and Chemical Composition of Dialysate:

  • Function: Diffusively removes uremic waste products while re-establishing systemic electrolyte and acid-base equilibrium. Dialysate contains zero waste products (no urea or creatinine).
  • Acid Concentrate Components: Formulated with sodium chloride, potassium chloride, magnesium chloride, calcium chloride, dextrose, and an acidifier (acetic acid or citric acid). Potassium and calcium levels are adjusted via physician orders.
  • Bicarbonate Concentrate Components: Formulated with sodium bicarbonate and sodium chloride; generates bicarbonate ions to neutralize metabolic acids and correct metabolic acidosis.

• Quality Assurance Water and Dialysate Testing Protocols:

  • Dialysate Temperature:
    • Frequency: Verified prior to the initiation of each treatment.
    • Target: Prescribed by physician. Temperature exceeding $107^\circ\text{F}\ (42^\circ\text{C})$ causes thermal hemolysis. Dialysate that is too cool induces patient shivering, discomfort, and decreases diffusive solute clearance.
  • Conductivity:
    • Definition: The capacity of an aqueous solution to conduct an electrical current, directly reflecting sodium concentration; determines the proportioning of acid concentrate, bicarbonate concentrate, and purified product water.
    • Frequency: Tested prior to each treatment before attaching Hansen connectors to the dialyzer.
    • Sample Site: Collected from the blue dialysate supply line.
    • Acceptable Range: Independent external meter reading must align within $\pm 0.3\,\text{mS/cm}$ of the machine display.
    • Testing Devices: Evaluated using a pHoenix meter, pHoenix XL meter, Myron L D1 meter, or Myron L D6 meter. (External meter verification is not required on BlueStar software-enabled machines using the bibag system for automated independent conductivity/pH).
    • Clinical Risks: Low conductivity (hypotonic dialysate) causes water to shift into red blood cells, causing cell swelling and acute hemolysis. High conductivity (hypertonic dialysate) draws water out of erythrocytes, producing crenation (cellular dehydration and shriveling).
  • Dialysate pH:
    • Definition: Quantitative measurement of the hydrogen ion concentration (acidity vs. alkalinity) of the final dialysate solution to verify proper acid and bicarbonate proportioning.
    • Frequency: Tested prior to each treatment before attaching Hansen connectors, and whenever acid concentrate jugs are switched (e.g., transitioning from a $1\,\text{K}$ to a $2\,\text{K}$ formulation).
    • Sample Site: Collected directly from the blue dialysate supply line.
    • Acceptable Ranges: pH of $6.9\text{--}7.6$ using pHoenix or Myron L D6 digital meters; pH of $7.0\text{--}7.4$ when using colorimetric pH chemical test strips.
  • Residual Bleach Testing:
    • Indication: Confirms the complete evacuation of sodium hypochlorite from internal hydraulic pathways following machine chemical disinfection.
    • Frequency: Tested prior to initiating treatment.
    • Expected Result: Negative.
  • Routine Total Chlorine Testing:
    • Frequency: Performed prior to the first patient treatment shift of the day, and repeated at intervals not to exceed every $4\,\text{hours}$.
    • Sample Site: Collected from the sample port located post-Worker Carbon Tank.
    • AAMI Action Standard: Total chlorine concentration must measure strictly less than $0.10\,\text{ppm}$. If total chlorine is $0.10\,\text{ppm}$ or greater, immediate secondary breakthrough testing must be initiated.
    • Step-by-Step Procedure: Use unexpired RPC Ultra Low Total Chlorine Test Strips. Ensure the Reverse Osmosis ($\text{RO}$) unit has run continuously for at least $15\,\text{minutes}$. Flush the designated sample port for at least $2\,\text{minutes}$. Rinse a clean sample cup with the sample water. Collect a $100\,\text{mL}$ water sample. Submerge the test strip in the sample for $60\,\text{seconds}$, moving it back and forth at a continuous, gentle rate. Remove the strip and shake once briskly to remove excess water. Wait precisely $20\,\text{seconds}$ for reaction color development. Compare the strip against the diagnostic color chart immediately. The matching color block indicates the Total Chlorine Level ($\text{TCL}$).
  • Breakthrough Chlorine Testing Protocol:
    • Trigger: Initiated when the Worker Carbon Tank post-sample equals or exceeds $0.10\,\text{ppm}$.
    • Frequency: Tested every $2\,\text{hours}$.
    • Sample Site: Collected from the sample port located post-Polisher Carbon Tank.
    • Intervention Threshold: Total chlorine post-polisher must remain below $0.10\,\text{ppm}$. If the post-polisher chlorine level reaches $0.10\,\text{ppm}$ or greater, notify the RN immediately and terminate all treatments to prevent patient exposure to chlorinated water.

• Machine Fluid Pathway Disinfection Schedules:

  • Acid Clean: Executed at the conclusion of every clinical treatment day; dissolves and flushes out accumulated bicarbonate precipitates and mineral scale.
  • Heat Disinfection: Performed following the daily acid clean cycle; circulates water heated to approximately $80^\circ\text{C}$ through the hydraulics to disinfect pathways.
  • Bleach Disinfection: Executed at least weekly; circulates a chemical bleach solution throughout internal hydraulic lines to dissolve organic matter and disinfect the system.